180 related articles for article (PubMed ID: 11260271)
1. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.
Björkman S; Shapiro AD; Berntorp E
Haemophilia; 2001 Mar; 7(2):133-9. PubMed ID: 11260271
[TBL] [Abstract][Full Text] [Related]
2. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
Björkman S
Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
4. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
Preijers T; Hazendonk HCAM; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA
J Thromb Haemost; 2017 Sep; 15(9):1737-1746. PubMed ID: 28688133
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring.
Björkman S
Haemophilia; 2013 Sep; 19(5):753-7. PubMed ID: 23731351
[TBL] [Abstract][Full Text] [Related]
6. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
Carlsson M; Björkman S; Berntorp E
Haemophilia; 1998 Mar; 4(2):83-8. PubMed ID: 9873843
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B.
Suzuki A; Tomono Y; Korth-Bradley JM
Haemophilia; 2016 Sep; 22(5):e359-66. PubMed ID: 27353956
[TBL] [Abstract][Full Text] [Related]
8. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.
Björkman S
Haemophilia; 2013 Nov; 19(6):808-13. PubMed ID: 23786333
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis in factor IX deficiency product and patient variation.
Kisker CT; Eisberg A; Schwartz B;
Haemophilia; 2003 May; 9(3):279-84. PubMed ID: 12694518
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
Alamelu J; Bevan D; Sorensen B; Rangarajan S
J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.
Chang HH; Yang YL; Hung MH; Tsay W; Shen MC
J Formos Med Assoc; 2007 Apr; 106(4):281-7. PubMed ID: 17475604
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
16. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.
Rocca A; Pizzinelli S; Oliovecchio E; Santagostino E; Rocino A; Iorio A;
Blood Transfus; 2011 Jan; 9(1):60-9. PubMed ID: 21084016
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
Björkman S
Haemophilia; 2003 May; 9 Suppl 1():101-8; discussion 109-10. PubMed ID: 12709045
[TBL] [Abstract][Full Text] [Related]
18. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
[TBL] [Abstract][Full Text] [Related]
20. Continuous infusion factor replacement in haemophilia B during and after cardiac surgery: the better choice?
Farid S; Sewaralthahab S; Smith HP
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]